Entera Bio (NASDAQ:ENTX - Get Free Report) posted its quarterly earnings data on Friday. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.01, Zacks reports. The firm had revenue of $0.04 million for the quarter.
Entera Bio Price Performance
ENTX traded down $0.07 on Friday, reaching $2.15. The company's stock had a trading volume of 8,407 shares, compared to its average volume of 75,643. Entera Bio has a 1 year low of $1.41 and a 1 year high of $2.79. The business's 50 day moving average is $1.92 and its 200 day moving average is $2.03. The stock has a market cap of $97.66 million, a price-to-earnings ratio of -8.27 and a beta of 1.51.
Analysts Set New Price Targets
Separately, HC Wainwright reaffirmed a "buy" rating and set a $10.00 price target on shares of Entera Bio in a research note on Tuesday, March 18th.
Get Our Latest Stock Report on ENTX
Entera Bio Company Profile
(
Get Free Report)
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Entera Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entera Bio wasn't on the list.
While Entera Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
